Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Australian Clinical Labs Ltd ( (AU:ACL) ) has issued an announcement.
Australian Clinical Labs Limited has announced an update regarding its ongoing share buy-back program. As of November 27, 2025, the company has repurchased a total of 1,231,319 shares, with 27,843 shares bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Limited operates in the healthcare industry, providing pathology services and diagnostic testing. The company focuses on delivering high-quality laboratory services across Australia, catering to both private and public healthcare sectors.
Average Trading Volume: 817,012
Technical Sentiment Signal: Hold
Current Market Cap: A$552M
Find detailed analytics on ACL stock on TipRanks’ Stock Analysis page.